News Drug Development

Pfizer Inc. Depression Drug Edronax Ineffective, May Be Harmful, Study in British Medical Journal Says

October 13, 2010 |

1 min read

LONDON, Oct 13 (Reuters) - Pfizer's (PFE.N) antidepressant reboxetine is an "ineffective and potentially harmful" drug and published data on it overestimates the benefits and underplays the risks, a study by German researchers said on Wednesday.

Clinical research Postmarket research Europe

Pfizer

MORE ON THIS TOPIC

Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.

Duchenne muscular dystrophy

Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment

January 26, 2026

·

2 min read

·

Dan Samorodnitsky

Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal

Ovarian cancer

Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie

January 26, 2026

·

2 min read

·

Tristan Manalac

Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.

Immunology and inflammation

Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway

January 23, 2026

·

2 min read

·

Tristan Manalac

Start early or business advantage. Businessman starts running ahead of competitors vector

Pain

Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill

January 22, 2026

·

2 min read

·

Tristan Manalac